STORM Therapeutics Secures $56 Million Series C Financing and Doses First Patient in Ph 2 Sarcoma Trial of STC‑15
Jerry McMahon, Chief Executive Officer of STORM Therapeutics, said: “Advancing our first‑in‑class METTL3 inhibitor, STC-15, into Phase 2 clinical development marks a pivotal breakthrough in tackling cancers characterized by aberrant cell differentiation. This milestone highlights our scientific innovation and the potential to create new therapeutic options for patients with substantial unmet needs. We are grateful for the steadfast support from our investors and are encouraged by the robust durability and activity demonstrated with STC-15 in Phase 1 studies. As we begin our Phase 2 trial, our focus remains on addressing critical unmet needs in sarcoma for the benefit of patients.”
Share:
More News
“Initiation of the TEADCO Phase 1b/2 basket trial is another important milestone for the ODM-212 clinical development program and reflects our commitment to patients with difficult-to-treat cancers,” said Professor Outi Vaarala, Executive Vice President, Research & Development at Orion. “Together with the ongoing TEADES study, TEADCO highlights the versatility of
“In this study, tovecimig showed an impressive overall response rate which translated into a clinically meaningful and highly statistically significant improvement in PFS for patients with previously treated BTC. The remarkable 56% reduction in the risk of disease progression is unprecedented in this patient population without an actionable mutation in
“We are encouraged to see taletrectinib (IBTROZI) added to the NCCN Guidelines® for CNS Cancers given its demonstrated high rates of intracranial response that are durable in ROS1+ NSCLC patients with brain metastases,” said David Hung, M.D., Founder, President and Chief Executive Officer of Nuvation Bio. “Given the prevalence of
Daniel Getts, Ph.D., CEO of CREATE, added “MT-304 is proof of what our platform can do, and what our team can execute. Our mRNA-LNP leadership enables us to move from concept to clinic with remarkable speed. Just last weekend at AACR, we presented compelling preclinical data across our in vivo